CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 21 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03428802
NCT03428802Phase 2Active
CompareCT.gov

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability

Rutgers, The State University of New Jersey·interventional·Posted Feb 12, 2018·Updated Apr 3, 2026

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Pembrolizumab for BRCA1 Gene Mutation and 19 related conditions. Active but no longer recruiting, targeting 21 participants across 2 sites.

Detailed Summary

This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2Active
2018201920202021202220232024202520262027
First PostedFeb 12, 2018
Enrollment StartMar 8, 2018
Primary CompletionNov 24, 2024
Study CompletionSep 21, 2027
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 8.4 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Pembrolizumabbiological

Given IV